Vitro Appoints Biocare Medical as Exclusive Distributor in the U.S. for NeoPATH Pro Instrument Launch at USCAP 2025

SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Vitro, a global developer, manufacturer and marketer of integral diagnostics solutions and data integration in Cancer Diagnostics, today announced that it has appointed Biocare Medical, a global leader in advanced staining solutions and reagents, as the exclusive distributor for its new NeoPATH Pro instrument in the United States. The NeoPATH Pro will officially debut at the 2025 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in Boston, MA.

The NeoPATH Pro is a high-throughput platform featuring a 42-slide capacity, supporting advanced immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH). The distribution agreement leverages Biocare Medical's extensive expertise and established presence in advanced staining solutions, providing U.S. laboratories with enhanced local support, service, and access to innovative diagnostic technology.

Luis de Luzuriaga, CEO of Biocare Medical, stated, "We are pleased that Vitro selected Biocare Medical as the exclusive distributor of the NeoPATH Pro in the United States. Our proven commercial excellence will ensure a successful introduction and adoption of NeoPATH Pro in the U.S. market, supporting laboratories in delivering enhanced diagnostic services to patients. This appointment highlights our reputation for excellence and reinforces our commitment to bringing cutting-edge diagnostic solutions to laboratories across the country."

Ferrán Prat, CEO of Vitro, added, "Choosing Biocare Medical as our exclusive U.S. distribution partner aligns perfectly with our strategy to introduce NeoPATH Pro effectively to the market. We look forward to launching at USCAP 2025, confident in Biocare's capability to deliver exceptional customer service and support."

About Biocare Medical

Biocare Medical is a globally recognized leader in advanced staining and reagent solutions for immunohistochemistry, in situ hybridization, and related diagnostic disciplines. Committed to innovation and quality, Biocare empowers pathologists and clinical laboratories worldwide to deliver accurate diagnoses and improved patient outcomes. For more information, visit www.biocare.net.

About Vitro

Vitro is a global specialized partner for integrated solutions in Cancer Diagnostics, with more than 30 years proven track record – Vitro is committed to deliver diagnostic excellence for all. With a reputation for innovation, reliability, and high-throughput capabilities, Vitro supports clinical laboratories in achieving exceptional diagnostic performance. For more information, visit www.vitro.bio.

Media Contact:
John Steel
9256038027
[email protected]

SOURCE Biocare Medical